StockTipsArenaBeta

BUY GlaxoSmithKline Pharmaceuticals Limited — Kunal Bothra

BUYGlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals share price target & all analyst calls

byKunal BothraHorizon: NA (inferred Swing (≤2wk))27 Aug 2026via ET Now (Live)

Entry₹3,103.2Inferred
Target₹3,200
Total upside +3.12% (call closed)
Stop loss₹3,050-1.71% risk
Exit₹3,05027 Aug 2026, 3:10 pm
Stop-loss hit-1.71%
Follow Kunal Bothra for new calls(30% target hit, 279 closed calls)Get alertsWatch GLAXO for new buy/sell callsGet alertsSee 150 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 27 Aug 2026
6 supporting1 neutral0 opposing
Supports the BUY call (6)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·19 Aug · 1w ago

GSK India Shares Rise Amid Strong FY26 Results and Dividend

NewsGoogle News·18 Aug · 1w ago

(opens in new tab)

GSK India Share Price: शेअर ₹2,758 वर, ₹57 डिव्हिडंड आणि दमदार प्रॉफिटची बातमी

NewsGoogle News·18 Aug · 1w ago

(opens in new tab)

GSK India Share Price: ਨਿਵੇਸ਼ਕਾਂ ਦੀ ਹੋਈ ਮੌਜ! FY26 ਦੇ ਸ਼ਾਨਦਾਰ ਨਤੀਜੇ, **₹57** ਡਿਵੀਡੈਂਡ ਦਾ ਐਲਾਨ

NewsGoogle News·18 Aug · 1w ago

(opens in new tab)

GSK ఇండియా షేర్ ర్యాలీ: FY26 ఫలితాలు, డివిడెండ్ తో ఇన్వెస్టర్లకు ఊరట

NewsGoogle News·18 Aug · 1w ago

(opens in new tab)
Neutral / worth noting (1)

GSK Pharmaceuticals: Addresses Increased Security Trading Volume

NewsGoogle News·26 Aug · yesterday

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on GlaxoSmithKline Pharmaceuticals

All analyst calls on GlaxoSmithKline Pharmaceuticals

More from Kunal Bothra

Every call and its outcome